Medicare Price Inflation Penalties Unlikely To Spur Greater Price Increases, Study Suggests
Results of an analysis published in JAMA could undercut arguments against legislative proposals establishing inflation penalties in Medicare.
You may also be interested in...
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.
It’s not quite the rebate rule, but final reg aims for ‘a reduction in the use of rebates and other price concessions’ driven by the transparency requirement and broad definitions. PCMA warns that ‘mandating an increased level of disclosure for this information could result in higher prescription drug prices for consumers.’
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.